Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levoleucovorin

FDA-approved product (powder, intravenous), marketed as Khapzory, Fusilev, Levoleucovorin Calcium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levoleucovorin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Anemia
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Osteosarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Levoleucovorin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levoleucovorin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer

    NCT05673772 · start 2020-10-23

    Registered record
    Registry ID
    NCT05673772
    Conditions
    Rectal Cancer
    Interventions
    short-course radiotherapy; mFOLFOX6; Chemoradiotherapy; TME surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-10-23
    Completion
    2031-12-28
    Enrolment
    364

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    Interventionshort-course radiotherapy; mFOLFOX6; Chemoradiotherapy; TME surgery
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

    NCT04083235 · start 2020-02-11

    Registered record
    Registry ID
    NCT04083235
    Conditions
    Metastatic Adenocarcinoma of the Pancreas
    Interventions
    Irinotecan Liposomal Injection; Oxaliplatin; 5Fluorouracil; Leucovorin; Nab-paclitaxel; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-02-11
    Completion
    2025-02-18
    Enrolment
    770

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Adenocarcinoma of the Pancreas
    InterventionIrinotecan Liposomal Injection; Oxaliplatin; 5Fluorouracil; Leucovorin +2 more
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Eucaloric High-Protein Fiber Diet in Healthy Adults: A Repeated Single-Arm Clinical Trial

    NCT05455164 · start 2020-01-01

    Registered record
    Registry ID
    NCT05455164
    Conditions
    Dietary Exposure
    Interventions
    Isomalto Oligosaccharide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-01-01
    Completion
    2022-06-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDietary Exposure
    InterventionIsomalto Oligosaccharide
    PhaseNot applicable
    Registry statusCompleted

  • Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer

    NCT03879109 · start 2019-07-08

    Registered record
    Registry ID
    NCT03879109
    Conditions
    Rectal Cancer
    Interventions
    Chemotherapy FOLFIRINOX, 6 cycles; Radiochemotherapy; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-08
    Completion
    2026-02-10
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRectal Cancer
    InterventionChemotherapy FOLFIRINOX, 6 cycles; Radiochemotherapy; Surgery
    PhasePhase 3
    Registry statusCompleted

  • Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

    NCT03977233 · start 2019-06-12

    Registered record
    Registry ID
    NCT03977233
    Conditions
    Pancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma; Pancreatic Neoplasms; Pancreatic Cancer Non-resectable; Pancreatic Cancer Resectable
    Interventions
    Oxaliplatin; Leucovorin; Irinotecan Hydrochloride; 5-FU
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2019-06-12
    Completion
    2030-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Ductal Adenocarcinoma (PDAC); Cancer of Pancreas; Pancreatic Cancer, Adult; Pancreas Adenocarcinoma +3 more
    InterventionOxaliplatin; Leucovorin; Irinotecan Hydrochloride; 5-FU
    PhasePhase 2
    Registry statusRecruiting

  • Study of the Combination of Apatinib and POF

    NCT03707639 · start 2018-11

    Registered record
    Registry ID
    NCT03707639
    Conditions
    Gastric Adenocarcinoma
    Interventions
    Apatinib; POF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-11
    Completion
    2020-11
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma
    InterventionApatinib; POF
    PhasePhase 2
    Registry statusUnknown

  • The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy

    NCT03851913 · start 2018-07-01

    Registered record
    Registry ID
    NCT03851913
    Conditions
    Hepatocellular Carcinoma
    Interventions
    TAI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2024-08-31
    Enrolment
    344

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionTAI
    PhasePhase 3
    Registry statusUnknown

  • Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer

    NCT03406299 · start 2018-04-19

    Registered record
    Registry ID
    NCT03406299
    Conditions
    Biliary Tract Neoplasms
    Interventions
    Tegafur; Leucovorin; Oxaliplatin; Gemcitabine; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-04-19
    Completion
    2024-12-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBiliary Tract Neoplasms
    InterventionTegafur; Leucovorin; Oxaliplatin; Gemcitabine +1 more
    PhasePhase 2
    Registry statusCompleted

  • Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma

    NCT03822936 · start 2018-02-08

    Registered record
    Registry ID
    NCT03822936
    Conditions
    Cancer of Pancreas; Pancreas Adenocarcinoma; Resectable Pancreatic Cancer
    Interventions
    Preoperative chemotherapy; Preoperative radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2025-02-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Pancreas; Pancreas Adenocarcinoma; Resectable Pancreatic Cancer
    InterventionPreoperative chemotherapy; Preoperative radiotherapy
    PhasePhase 2
    Registry statusTerminated

  • PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

    NCT04151277 · start 2017-11-28

    Registered record
    Registry ID
    NCT04151277
    Conditions
    Neoplasms Pancreatic
    Interventions
    FOLFOX-A; Gemcitabe and Abraxane; G-CSF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-11-28
    Completion
    2026-01-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms Pancreatic
    InterventionFOLFOX-A; Gemcitabe and Abraxane; G-CSF
    PhasePhase 2
    Registry statusUnknown

  • Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects

    NCT03258762 · start 2017-09-25

    Registered record
    Registry ID
    NCT03258762
    Conditions
    Toxoplasmosis
    Interventions
    Pyrimethamine; Calcium folinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-25
    Completion
    2017-11-19
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToxoplasmosis
    InterventionPyrimethamine; Calcium folinate
    PhasePhase 1
    Registry statusCompleted

  • Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

    NCT03222089 · start 2017-07-20

    Registered record
    Registry ID
    NCT03222089
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Irinotecan; Oxaliplatin; Levoleucovorin; 5-FU; GM-CSF; IL-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-07-20
    Completion
    2020-07-20
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionIrinotecan; Oxaliplatin; Levoleucovorin; 5-FU +2 more
    PhasePhase 2
    Registry statusWithdrawn

  • Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers

    NCT02934464 · start 2016-12

    Registered record
    Registry ID
    NCT02934464
    Conditions
    Stomach Neoplasms
    Interventions
    RAMUCIRUMAB; Paclitaxel; FOLFOX 4; mFOLFOX 6; XELOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2016-12
    Completion
    2021-12
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStomach Neoplasms
    InterventionRAMUCIRUMAB; Paclitaxel; FOLFOX 4; mFOLFOX 6 +1 more
    PhasePhase 3
    Registry statusUnknown

  • FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer

    NCT02581462 · start 2016-06

    Registered record
    Registry ID
    NCT02581462
    Conditions
    Stomach Cancer; Gastroesophageal Junction Cancer
    Interventions
    FLOT alone; FLOT + Herceptin/Pertuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2016-06
    Completion
    2020-07-17
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStomach Cancer; Gastroesophageal Junction Cancer
    InterventionFLOT alone; FLOT + Herceptin/Pertuzumab
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

    NCT02296671 · start 2015-02

    Registered record
    Registry ID
    NCT02296671
    Conditions
    Esophagogastric Cancer
    Interventions
    Pemetrexed; Oxaliplatin; Leucovorin; Fluorouracil; Germline genotyping analyses for TSER
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2015-02
    Completion
    2022-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophagogastric Cancer
    InterventionPemetrexed; Oxaliplatin; Leucovorin; Fluorouracil +1 more
    PhasePhase 2
    Registry statusWithdrawn